CR8709A - Tratamiento de la hemorragia de disrupcion en regimenes anticonceptivos extendidos - Google Patents

Tratamiento de la hemorragia de disrupcion en regimenes anticonceptivos extendidos

Info

Publication number
CR8709A
CR8709A CR8709A CR8709A CR8709A CR 8709 A CR8709 A CR 8709A CR 8709 A CR8709 A CR 8709A CR 8709 A CR8709 A CR 8709A CR 8709 A CR8709 A CR 8709A
Authority
CR
Costa Rica
Prior art keywords
hemorragy
conceptive
regimes
disruption
treatment
Prior art date
Application number
CR8709A
Other languages
English (en)
Spanish (es)
Inventor
Andreas Sachse
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35056905&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR8709(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of CR8709A publication Critical patent/CR8709A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Steroid Compounds (AREA)
CR8709A 2004-04-30 2006-10-25 Tratamiento de la hemorragia de disrupcion en regimenes anticonceptivos extendidos CR8709A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US56644304P 2004-04-30 2004-04-30
US57502404P 2004-05-28 2004-05-28
US57719904P 2004-06-07 2004-06-07
US63838004P 2004-12-27 2004-12-27
US66006805P 2005-03-10 2005-03-10

Publications (1)

Publication Number Publication Date
CR8709A true CR8709A (es) 2007-08-28

Family

ID=35056905

Family Applications (1)

Application Number Title Priority Date Filing Date
CR8709A CR8709A (es) 2004-04-30 2006-10-25 Tratamiento de la hemorragia de disrupcion en regimenes anticonceptivos extendidos

Country Status (29)

Country Link
US (3) US8163721B2 (enExample)
EP (1) EP1747001B1 (enExample)
JP (4) JP2007535519A (enExample)
KR (4) KR20130022425A (enExample)
CN (1) CN103127156A (enExample)
AR (1) AR048722A1 (enExample)
AU (1) AU2005237255B2 (enExample)
BR (1) BRPI0510493A (enExample)
CA (1) CA2562296A1 (enExample)
CR (1) CR8709A (enExample)
DK (1) DK1747001T3 (enExample)
EA (2) EA031227B1 (enExample)
EC (1) ECSP066999A (enExample)
ES (1) ES2704999T3 (enExample)
HU (1) HUE041475T2 (enExample)
IL (1) IL178458A (enExample)
LT (1) LT1747001T (enExample)
MX (1) MXPA06012567A (enExample)
MY (1) MY151322A (enExample)
NO (1) NO341685B1 (enExample)
NZ (1) NZ586107A (enExample)
PA (1) PA8631801A1 (enExample)
PE (1) PE20060467A1 (enExample)
SG (2) SG10201701904TA (enExample)
SI (1) SI1747001T1 (enExample)
SV (1) SV2006002100A (enExample)
TW (1) TWI374735B (enExample)
UY (1) UY28875A1 (enExample)
WO (1) WO2005105103A2 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020132801A1 (en) * 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
MY151322A (en) 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
US20070111975A1 (en) 2004-10-07 2007-05-17 Duramed Pharmaceuticals, Inc. Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens
US20070088010A1 (en) * 2005-10-17 2007-04-19 Doris Huebler Method of making a single-stage pharmaceutical preparation for oral therapy of dysfunctional uterine bleeding, containing ethinyl estradiol and dienogest
EP1977752A1 (de) * 2007-03-01 2008-10-08 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Zubereitung zur Verminderung der Endometriose
DE102007011105A1 (de) * 2007-03-02 2008-09-04 Bayer Schering Pharma Aktiengesellschaft Mineralcorticoid-Rezeptor-Antagonisten zur Behandlung von Endometriose
WO2010033188A2 (en) * 2008-09-16 2010-03-25 Playtex Products, Llc. Dosages for menstrual suppression, contraception, and hormone replacement therapy, and methods of administering same
US9192614B2 (en) 2008-10-08 2015-11-24 Agile Therapeutics, Inc. Contraceptive transdermal delivery of hormones
ES2734510T3 (es) 2008-10-08 2019-12-10 Agile Therapeutics Inc Administración transdérmica
ES2795455T3 (es) 2008-10-08 2020-11-23 Agile Therapeutics Inc Suministro transdérmico
EP2410859A4 (en) 2009-03-27 2013-03-13 Agile Therapeutics Inc TRANSDERMAL ADMINISTRATION
US11351122B1 (en) 2010-07-28 2022-06-07 Laboratorios Leon Farma Sa Synthetic progestogens and pharmaceutical compositions comprising the same
AR081670A1 (es) 2010-06-29 2012-10-10 Leon Farma Sa Lab Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
US10849857B2 (en) 2010-07-28 2020-12-01 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
US9603860B2 (en) 2010-07-28 2017-03-28 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
SMT202100350T1 (it) 2015-06-18 2021-07-12 Estetra Sprl Pastiglia orodispersibile contenente etetrolo
CN107810001A (zh) 2015-06-18 2018-03-16 密特拉制药公司 含雌四醇的口腔分散片剂
NZ776452A (en) 2015-06-18 2024-11-29 Estetra Srl Orodispersible dosage unit containing an estetrol component
DK3106148T3 (en) 2015-06-18 2018-05-07 Mithra Pharmaceuticals S A Orodispersible dosing unit containing an estetrol component
JP6827962B2 (ja) * 2015-06-23 2021-02-10 ラボラトリオス レオン ファーマ エスエー 過剰体重に影響される女性患者のためのドロスピレノン系避妊薬
KR102712911B1 (ko) 2016-08-05 2024-10-04 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법
HRP20220708T4 (hr) 2016-09-30 2025-04-25 Sumitomo Pharma Switzerland Gmbh Postupci liječenja fibroida maternice i endometrioze
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物
US12138270B2 (en) 2021-09-07 2024-11-12 Millicent Pharma Limited Contraceptive regimen including reduced level of estrogen

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5244096A (en) 1988-04-22 1993-09-14 Stoner Fred L Preventive treatment kit against sexually transmitted disease
AU3473193A (en) 1992-01-17 1993-08-03 Procter & Gamble Company, The Treatment for atherosclerosis
DE4344462C2 (de) * 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
US5552394A (en) 1994-07-22 1996-09-03 The Medical College Of Hampton Roads Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy
US6451778B1 (en) * 1996-07-26 2002-09-17 Wyeth Oral contraceptive
JP2000515890A (ja) * 1996-07-26 2000-11-28 アメリカン・ホーム・プロダクツ・コーポレイション プロゲスチンとエストロゲンとの混合剤からなる一相性避妊法およびキット
US5842441A (en) 1996-08-26 1998-12-01 Pharmalett Denmark A/S Medicated and individualized treatment shampoo for dermatological disturbances of companion animals
US5898032A (en) 1997-06-23 1999-04-27 Medical College Of Hampton Roads Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
DE19739916C2 (de) * 1997-09-11 2001-09-13 Hesch Rolf Dieter Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
DK1598069T3 (da) 1999-08-31 2009-07-06 Bayer Schering Pharma Ag Farmaceutisk præparat af ethinylestradiol og drospirenon til anvendelse som præventionsmiddel
US6787531B1 (en) * 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
CO5271709A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos
US6653298B2 (en) * 2000-01-14 2003-11-25 Sterix Limited Composition
DE10045380A1 (de) * 2000-09-14 2002-04-04 Schering Ag Verfahren zur Kontrazeption und dessen Darreichungsform
IL145876A0 (en) 2000-10-17 2002-07-25 Pfizer Prod Inc Methods and kits for improving vascular health
US20020193356A1 (en) * 2001-05-23 2002-12-19 Van Beek Agatha Antonia Magdalena Means and method for hormonal contraception
US20030018018A1 (en) 2001-07-10 2003-01-23 Medical College Of Hampton Roads Ultra low dose oral contraceptives with sustained efficacy and induced amenorrhea
MY151322A (en) * 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
US8501720B2 (en) 2004-07-30 2013-08-06 Bayer Pharma AG Method for treatment of dysmenorrhea

Also Published As

Publication number Publication date
WO2005105103A3 (en) 2006-09-08
EA016625B1 (ru) 2012-06-29
US20050250747A1 (en) 2005-11-10
KR20070004919A (ko) 2007-01-09
HUE041475T2 (hu) 2019-05-28
MXPA06012567A (es) 2006-12-15
US20150174142A1 (en) 2015-06-25
ECSP066999A (es) 2006-12-29
MY151322A (en) 2014-05-15
WO2005105103A2 (en) 2005-11-10
JP6153967B2 (ja) 2017-06-28
CA2562296A1 (en) 2005-11-10
PE20060467A1 (es) 2006-06-11
AR048722A1 (es) 2006-05-17
BRPI0510493A (pt) 2007-11-13
TW200603781A (en) 2006-02-01
TWI374735B (en) 2012-10-21
NO20065499L (no) 2006-11-29
NO341685B1 (no) 2017-12-18
KR20130022425A (ko) 2013-03-06
EA031227B1 (ru) 2018-12-28
EA201200377A8 (ru) 2018-01-31
JP2015187157A (ja) 2015-10-29
JP2017048253A (ja) 2017-03-09
UY28875A1 (es) 2005-11-30
IL178458A (en) 2016-08-31
JP2007535519A (ja) 2007-12-06
EP1747001B1 (en) 2018-10-10
EA201200377A1 (ru) 2012-08-30
US8163721B2 (en) 2012-04-24
KR20150058555A (ko) 2015-05-28
AU2005237255A1 (en) 2005-11-10
ES2704999T3 (es) 2019-03-21
KR101812160B1 (ko) 2017-12-27
SG152288A1 (en) 2009-05-29
NZ586107A (en) 2012-05-25
SI1747001T1 (sl) 2019-02-28
US20120202779A1 (en) 2012-08-09
AU2005237255B2 (en) 2011-07-07
EA200601908A1 (ru) 2007-04-27
DK1747001T3 (en) 2019-02-04
IL178458A0 (en) 2008-04-13
CN103127156A (zh) 2013-06-05
JP2013018787A (ja) 2013-01-31
EP1747001A2 (en) 2007-01-31
KR20160150113A (ko) 2016-12-28
PA8631801A1 (es) 2006-11-09
SV2006002100A (es) 2006-02-15
SG10201701904TA (en) 2017-05-30
JP6134491B2 (ja) 2017-05-24
LT1747001T (lt) 2019-01-25

Similar Documents

Publication Publication Date Title
CR8709A (es) Tratamiento de la hemorragia de disrupcion en regimenes anticonceptivos extendidos
CY1120879T1 (el) Πολλαπλου συστατικου βιοδραστικος ενδοκολπικος δακτυλιος
ECSP088097A (es) Nuevos regímenes para dispositivos de administración controlada de fármacos para anticoncepción
CR7610A (es) Uso de derivados de thio-oxindol en el tratamiento de condiciones realcionadas con la hormona
CL2007001961A1 (es) Composicion farmaceutica que contiene a) 2,0 mg de dienogest y 0,015 mg de etinilestradiol y (6s)-5-metil-tetrahidrofolato y uno o mas excipiente/vehiculos; kit; uso para la anticoncepcion femeneina y reducir el riesgo d malformaciones congenitas debidas a la falta de folato en el embarazo.
AR040130A1 (es) Esteres de etonogestrel, su uso como anticopceptivo y para el tratamiento de desordenes ginecologicos
ES2195573T3 (es) Preparado farmaceutico solido con estructura multifase para administracion oral de gatifloxacina o sus sales o hidratos farmaceuticamente utilizables y procedimiento para su preparacion.
AR031601A1 (es) Derivados de 4-pirimidinamina, composiciones farmaceuticas y metodos relacionados
CL2008000999A1 (es) Composicion farmaceutica que comprende drospirenona y 17beta estradiol; kit farmaceutico que comprende a dicha composicion, util para terapia hormonal y contracepcion en mujeres.
AR043013A1 (es) Composicion farmaceutica destinada al tratamiento de la endometriosis
CU23637B6 (es) Tratamiento de la hemorragia de disrupción en regímenes anticonceptivos extendidos
CL2011000252A1 (es) Uso de estriol para preparar un medicamento util en la prevencion y/o el tratamiento de atrofia urogenital en mujeres.
PL1869185T3 (pl) Koniugat zawierający białko P21 do leczenia raka
DOP2006000257A (es) Derivados de 9-cloro-15-desoxiprostaglandina, procesos para su preparación y su uso como medicamento
TW200744610A (en) New regimens for controlled drug delivery devices for contraception
BRPI0513825A (pt) combinações de epotilona
CL2008001147A1 (es) Combinacion farmaceutica que comprende 11b-(4-acetilfenil)-17b-hidroxi-17 (1,1,2,2,2-pentafluoroetil) estra-4,9-dien-3-ona junto con al menos un antiestrogeno no esteroidal puro; y uso para la profilaxis o el tratamientodel cancer mediado por brca1 o brca2.
AR049195A1 (es) Uso de una combinacion de etinilestradiol y acetato de clormadinona para la preparacion de un medicamento
BRPI0510906A (pt) composição farmacêutica tópica, composição para administração tópica e seu uso
CL2008001148A1 (es) Combinacion farmaceutica que comprende un antagonista del receptor de progesterona 11beta-(4-acetilfenil)-17beta-hidroxi-17alfa-(1,1,2,2,2-pentafluoroetil)-estra-4,9-dien-3-ona y un antiestrogeno; y su uso para el tratameinto del cancer de mama.
AR049220A1 (es) Uso de 7-ter-butoxiiminometilcamptotecina en la preparacion de un medicamento util para el tratamiento de neoplasmas uterinos
PE20070555A1 (es) Uso de valerato de estradiol en combinacion con dienogest para la terapia oral de la hemorragia uterina disfuncional unida con una anticoncepcion oral
AR044067A1 (es) Combinaciones de principio activo y terapias para combatir el abuso de alcohol
GT200500099A (es) Tratamiento de la hemorragia de disrupcion en regimenes anticonceptivos extendidos
AR048355A1 (es) Asociacion entre un compuesto heterociclico y un agente antioxidante y las composiciones farmaceuticas que los contienen

Legal Events

Date Code Title Description
FC Refusal